Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Other Working Capital Changes (2016 - 2025)

IGC Pharma (IGC) has disclosed Other Working Capital Changes for 16 consecutive years, with -$37000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Working Capital Changes rose 77.84% to -$37000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$271000.0, a 120.33% decrease, with the full-year FY2025 number at -$100000.0, up 33.33% from a year prior.
  • Other Working Capital Changes was -$37000.0 for Q3 2025 at IGC Pharma, up from -$183000.0 in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $434000.0 in Q4 2022 to a low of -$510000.0 in Q1 2022.
  • A 5-year average of -$57368.4 and a median of -$34000.0 in 2023 define the central range for Other Working Capital Changes.
  • Peak YoY movement for Other Working Capital Changes: crashed 1027.27% in 2022, then surged 521.43% in 2024.
  • IGC Pharma's Other Working Capital Changes stood at -$181000.0 in 2021, then skyrocketed by 339.78% to $434000.0 in 2022, then crashed by 121.43% to -$93000.0 in 2023, then soared by 78.49% to -$20000.0 in 2024, then plummeted by 85.0% to -$37000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Other Working Capital Changes are -$37000.0 (Q3 2025), -$183000.0 (Q2 2025), and -$31000.0 (Q1 2025).